Clinical TrialAug 13, 2026, 08:16 AM
Eupraxia Reports Positive Phase 1b/2a RESOLVE Trial Data for EP-104GI
AI Summary
Eupraxia Pharmaceuticals announced positive symptom response data from a new analysis of its ongoing Phase 1b/2a RESOLVE trial for EP-104GI in Eosinophilic Esophagitis (EoE) patients. The analysis showed significant reductions in both odynophagia (painful swallowing) and dysphagia (difficulty swallowing) severity, with improvements sustained up to 52 weeks. EP-104GI continues to be well tolerated, with no treatment-emergent or procedure-related Serious Adverse Events reported across over 130 patients.
Key Highlights
- Moderate to severe odynophagia reduced from 62% at baseline to 25% at 24-52 weeks in Cohorts 7-9.
- No patients reported severe odynophagia at 24 and 52 weeks, down from 23% at baseline.
- Moderate to severe dysphagia reduced from 77% at baseline to 25% at 24 and 52 weeks in Cohorts 7-9.
- No patients reported severe dysphagia at 24 and 52 weeks, down from 31% at baseline.
- 50% of patients reported no odynophagia at 52 weeks, up from 15% at baseline.
- Over 130 patients treated with EP-104GI or placebo with no reported Serious Adverse Events (SAEs).
Price Impact
More from EPRX